Repligen Corp
RGEN
View Detailed Chart
157.390USD
-4.270-2.64%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
8.86BMarket Cap
5641.22P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.64%
5 Days
-4.60%
1 Month
-0.39%
6 Months
+19.87%
Year to Date
+9.34%
1 Year
+0.90%
View Detailed Chart
TradingKey Stock Score of Repligen Corp
Currency: USD Updated: 2025-12-12Key Insights
Repligen Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 19/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 187.96.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repligen Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
187.959
Target Price
+16.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repligen Corp Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 5641.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.23M shares, decreasing 10.18% quarter-over-quarter.
Held by Scotia Canadian Dividend Fund
Star Investor Scotia Canadian Dividend Fund holds 40.66K shares of this stock.
Repligen Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Repligen Corp Info
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Ticker SymbolRGEN
CompanyRepligen Corp
CEOLoeillot (Olivier)
Websitehttps://www.repligen.com/
FAQs
What is the current price of Repligen Corp (RGEN)?
The current price of Repligen Corp (RGEN) is 157.390.
What is the symbol of Repligen Corp?
The ticker symbol of Repligen Corp is RGEN.
What is the 52-week high of Repligen Corp?
The 52-week high of Repligen Corp is 182.520.
What is the 52-week low of Repligen Corp?
The 52-week low of Repligen Corp is 102.965.
What is the market capitalization of Repligen Corp?
The market capitalization of Repligen Corp is 8.86B.
What is the net income of Repligen Corp?
The net income of Repligen Corp is -25.51M.
Is Repligen Corp (RGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Repligen Corp (RGEN) has an overall rating of Buy, with a price target of 187.959.
What is the Earnings Per Share (EPS TTM) of Repligen Corp (RGEN)?
The Earnings Per Share (EPS TTM) of Repligen Corp (RGEN) is 0.028.
Related Instruments
+1.52%
+1.77%
-1.14%
-0.92%
-2.60%
+0.90%
+0.32%
+0.12%
+0.50%
-1.74%
-0.32%
+0.90%
+0.44%
+0.23%
-0.47%
-1.38%
-2.23%
+0.05%
-2.43%
-0.05%
